Workflow
启迪药业:上半年净亏损0.17亿元

Core Viewpoint - Qidi Pharmaceutical reported a decline in revenue for the first half of 2025, indicating potential challenges in its business operations [1] Financial Performance - The company achieved operating revenue of 142 million yuan, a year-on-year decrease of 2.87% [1] - The net profit attributable to shareholders of the listed company was -17 million yuan, showing a year-on-year increase of 26.61% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -23 million yuan, reflecting a year-on-year increase of 7.12% [1] - Basic earnings per share were -0.0717 yuan [1]